IRF3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL22119612	1.00	1/20
SCHEMBL19449091	0.88	1/20
SCHEMBL22135304	0.88	1/20
SCHEMBL22135297	0.86	1/20
SCHEMBL22119594	0.85	1/20
SCHEMBL22119879	0.83	1/20
SCHEMBL22135069	0.81	1/20
SCHEMBL22119020	0.81	1/20
SCHEMBL22135102	0.80	1/20
SCHEMBL22119606	0.80	1/20
SCHEMBL22135034	0.80	1/20
SCHEMBL22135184	0.80	1/20
SCHEMBL22135219	0.79	1/20
SCHEMBL21648072	0.78	1/20
SCHEMBL25786359	0.77	1/20
SCHEMBL22135303	0.77	1/20
SCHEMBL22119952	0.75	1/20
SCHEMBL22134956	0.74	1/20
SCHEMBL22135286	0.74	1/20
SCHEMBL22134948	0.73	1/20

Clinical trials — most relevant to IRF3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Nebulized Heparin for the Treatment of COVID-19	PHASE4	COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies	PHASE3	UNKNOWN
Ivermectin and Nitazoxanide Combination Therapy for COVID-19	PHASE2/PHASE3	UNKNOWN
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19	PHASE2	UNKNOWN
A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer	PHASE2	RECRUITING
Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC	PHASE2	UNKNOWN
Tofacitinib for Immune Skin Conditions in Down Syndrome	PHASE2	COMPLETED
Effect of IFN-γ on Innate Immune Cells	PHASE1	COMPLETED
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts	nan	COMPLETED
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches	nan	UNKNOWN
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Hepatitis C in Clinically Discordant Hemophilic Siblings	nan	COMPLETED
Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis	nan	COMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN
Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile	nan	UNKNOWN
Ccf mtDNA as a Neurodegenerative Biomarker	nan	UNKNOWN
Viral and Epigenetic Influences in CRSwNP	nan	ACTIVE_NOT_RECRUITING
Gene Expression Profiling in Type 1 Diabetes	nan	COMPLETED
Immune Interactions in Severe Asthma	nan	COMPLETED
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia	nan	COMPLETED
Nasal Immune Challenge Study	nan	UNKNOWN
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient	nan	RECRUITING
Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)	nan	NOT_YET_RECRUITING
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort	nan	UNKNOWN
Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE	nan	RECRUITING
A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a IRF3 binder may also engage these)

Protein	Name	Similarity
Q4JF28	—	1.000	Q4JF28 →
Q764M6	—	1.000	Q764M6 →
P70671	—	1.000	P70671 →
P70434	—	0.998	P70434 →
Q02556	—	0.996	Q02556 →
Q00978	—	0.994	Q00978 →
Q61179	—	0.994	Q61179 →
Q90643	—	0.991	Q90643 →
Q92985	—	0.991	Q92985 →
Q5T124	—	0.990	Q5T124 →
O75064	—	0.989	O75064 →
P23611	—	0.988	P23611 →
Q15306	—	0.987	Q15306 →
Q90871	—	0.987	Q90871 →
Q8BHW9	—	0.986	Q8BHW9 →
Q8K330	—	0.986	Q8K330 →
Q3T1I9	—	0.985	Q3T1I9 →
Q9WVL2	—	0.985	Q9WVL2 →
ENGASE	Cytosolic endo-beta-N-acetylglucosaminidase	0.985	landscape →
Q8CIE4	—	0.985	Q8CIE4 →
Q6ZQA0	—	0.985	Q6ZQA0 →
P58660	—	0.985	P58660 →
Q8CFK6	—	0.985	Q8CFK6 →
Q9D572	—	0.984	Q9D572 →
ARHGEF1	Rho guanine nucleotide exchange factor 1	0.984	landscape →
Q5XIS1	—	0.984	Q5XIS1 →
Q5REG4	—	0.984	Q5REG4 →
Q9QZ28	—	0.984	Q9QZ28 →
A2D5H2	—	0.984	A2D5H2 →
Q1JPD6	—	0.983	Q1JPD6 →